Candel Therapeutics
Developing oncolytic viral immunotherapies that light up and empower the immune system to fight cancer.
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6063 %) | (6792 %) | (19534 %) | (40835 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (6592 %) | (14144 %) | (28899 %) | (15035 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5286 % | 7003 % | 12142 % | 16630 % | - | - |
Source: Company filings or news article
Related Content
Candel Therapeutics is at the forefront of developing innovative viral immunotherapies aimed at educating the immune system to recognize and eliminate tumor cells. The company operates in the oncology sector, focusing on creating treatments that combine anti-tumor and immune-stimulatory components. These therapies are designed to cause in situ vaccination against unique antigens and neoantigens presented when tumor cells lyse, thereby activating both innate and adaptive immune mechanisms.
Candel Therapeutics primarily serves patients with various forms of cancer, including those with non-small cell lung cancer (NSCLC) who have shown suboptimal responses to first-line anti-PD-L1 inhibitor therapy. The company is currently enrolling patients in multiple U.S. centers for a Phase 2 clinical trial.
The business model revolves around the development and clinical testing of these transformative immunotherapies, with revenue generated through partnerships, clinical trial enrollments, and eventual commercialization of successful treatments.
Candel Therapeutics aims to improve lives by fostering a collaborative and innovative environment, encouraging creativity and efficiency among its teams.
Keywords: viral immunotherapies, oncology, cancer treatment, immune system, tumor cells, NSCLC, clinical trials, in situ vaccination, antigens, neoantigens.